$-0.03 EPS Expected for Pharma-Bio Serv, Inc. (PBSV); Tronox LTD (TROX) Sentiment Is 2.06

March 9, 2018 - By Adrian Mccoy

Analysts expect Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) to report $-0.03 EPS on March, 16.They anticipate $0.01 EPS change or 50.00% from last quarter’s $-0.02 EPS. After having $-0.02 EPS previously, Pharma-Bio Serv, Inc.’s analysts see 50.00% EPS growth. It closed at $0.56 lastly. It is down 0.00% since March 9, 2017 and is . It has underperformed by 16.70% the S&P500.

Tronox Limited produces and markets titanium bearing mineral sands and titanium dioxide pigment in North America, Europe, South Africa, and the Asia-Pacific region. The company has market cap of $2.39 billion. It primarily operates in two divisions, TiO2 and Alkali. It currently has negative earnings. The TiO2 segment engages in the exploration, mining, and beneficiation of mineral sands deposits.

The stock decreased 1.74% or $0.35 during the last trading session, reaching $19.71. About 718,107 shares traded. Tronox Limited (TROX) has risen 311.09% since March 9, 2017 and is uptrending. It has outperformed by 294.39% the S&P500.

Credit Capital Investments Llc holds 12.56% of its portfolio in Tronox Limited for 539,502 shares. Fine Capital Partners L.P. owns 3.19 million shares or 7.06% of their US portfolio. Moreover, Private Capital Management Llc has 5.32% invested in the company for 1.66 million shares. The Connecticut-based Tide Point Capital Management Lp has invested 1.78% in the stock. Stelliam Investment Management Lp, a New York-based fund reported 2.66 million shares.

Pharma-Bio Serv, Inc., a compliance and technology transfer services consulting company, provides compliance consulting services to the pharmaceutical, biotechnology, medical device, and chemical manufacturing companies in Puerto Rico, the United States, Europe, and Brazil. The company has market cap of $12.92 million. The companyÂ’s technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. It currently has negative earnings. It also provides microbiological testing services and chemical testing services through its laboratory; and technical trainings/seminars.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: